Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution-Reference-Cited by-同舟云学术

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution

Published:2007-06-14 Issue:11 Volume:21 Page:2358-2359
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Stewart A K,Chang H,Trudel S,Anderson K C,Richardson P,Alsina M,Reece D,Young S,Sable-Hunt A,Li Z,Keats J,Van Wier S,Ahmann G,Price-Troska T,Giusti K,Bergsagel P L,Chesi M,Fonseca R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404800.pdf

Reference8 articles.

1. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489–3495.

2. Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68.

3. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105 (Suppl 7): 2941–2948.

4. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S . Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353–355.

5. Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005; 105: 4060–4069.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma;Journal of Zhejiang University-SCIENCE B;2019-12-21

2. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone;Blood Advances;2019-12-10

3. High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis;Biology of Blood and Marrow Transplantation;2019-02

4. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma;BioMed Research International;2015

5. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma;Leukemia Research;2014-05